Core Viewpoint - Investors in C3.ai, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's growth and the health of its CEO [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that from February 26, 2025, to August 8, 2025, C3.ai's management failed to disclose critical information, including the over-reliance on the CEO's health and effectiveness [2]. - Allegations include that the optimistic reports on growth, earnings potential, and margins were not reflective of the actual situation, as the CEO had not sufficiently recovered to fulfill his role [2]. Participation Information - Investors who suffered losses related to C3.ai are encouraged to participate in the lawsuit before the lead plaintiff deadline of October 21, 2025 [2]. - Interested parties can contact The Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Core Viewpoint - A class action securities lawsuit has been filed against KinderCare Learning Companies, Inc. due to alleged securities fraud affecting investors who purchased shares during the October 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to KinderCare Learning Companies, Inc. [2] - The complaint alleges that KinderCare concealed numerous incidents of child abuse, neglect, and harm at its facilities, failing to provide the highest quality care and meet minimum industry standards [3]. - As a result of these issues, KinderCare is said to be exposed to undisclosed risks including lawsuits, regulatory actions, negative publicity, reputational damage, and business loss [3]. Group 2: Next Steps for Investors - Investors who suffered losses in KinderCare Learning Companies, Inc. during the relevant timeframe have until October 14, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements and concealed information regarding LifeMD's competitive position and financial guidance for 2025 [1]. - It is alleged that the defendants did not properly account for rising customer acquisition costs in LifeMD's RexMD segment and related to obesity treatment drugs [1]. - The statements made by the defendants about LifeMD's business operations and prospects were claimed to be materially false and misleading [1]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff [2]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [2]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3].

Core Viewpoint - A class action securities lawsuit has been filed against Semler Scientific, Inc. for alleged securities fraud affecting investors between March 10, 2021, and April 15, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Semler Scientific failed to disclose a significant investigation by the U.S. Department of Justice regarding violations of the False Claims Act, while discussing potential violations in hypothetical terms [3]. - The complaint alleges that the public statements made by the defendants were materially false and misleading during the relevant time period [3]. Group 2: Investor Information - Investors who suffered losses in Semler Scientific during the specified timeframe have until October 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Legal Proceedings - Investors have until September 22, 2025, to request to lead the case in the U.S. District Court for the Central District of California, under the case caption Makaveev v. RxSight, Inc., et al., No. 25-cv-01596 [2]. Financial Performance - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors during the relevant period when the company promoted strong sales [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

美国司法部还表示，34岁的吴舰是一名居住在纽约的中国公民，目前处于在逃状态，无法立即确定他的律师。 近日，美国司法部表示，吴舰被指控犯有电汇欺诈、证券欺诈和洗钱罪。 每经编辑｜何小桃 曾在小红书晒出2350万美元（约合人民币1.67亿元）年薪的吴舰，正面临美国证券交易委员会和美国司法部的民事刑事双重起诉。 根据吴舰的Linkedin（领英）简介，他在2011年取得了清华大学的工学学士学位，并于2017年从美国康奈尔大学获得了哲学博士学位。 名校毕业的吴舰曾在美国知名做市商Citadel（城堡投资）实习，于2018年4月加入顶尖量化对冲基金Two Sigma，从量化研究员做起，三年时间不到就升任 Two Sigma量化研究部的副总裁，2023年1月，工作不到五年的吴舰被提拔为高级副总裁。 吴舰2023年曾在小红书"悄悄炫富"，并称"不敢发朋友圈，自己心态还是太年轻，想找个没人认识的地方偷偷炫耀下......"。该帖子显示，其2022年的薪资 相较往年出现暴涨，高达2350万美元。 美国证券交易委员会的起诉书称，在2021年11月至2023年8月期间，吴舰秘密操纵了他创建或帮助创建的至少14个投资模型，吴舰向Tw ...

Core Viewpoint - Tronox Holdings PLC is facing a class action lawsuit due to significant financial losses and misleading statements made by the company regarding its business operations and financial outlook during the Class Period from February 12, 2025, to July 30, 2025 [1][4]. Financial Performance - On July 30, 2025, Tronox reported a substantial decline in sales for its TiO2 product, attributing this to a "softer than anticipated coatings season and heightened competitive dynamics" [2]. - The company revised its 2025 financial outlook, lowering its full-year revenue guidance and cutting its dividend by 60% [2]. Stock Market Reaction - Following the release of the disappointing financial results, Tronox's stock price plummeted by $1.95, or 37.9%, closing at $3.19 per share on July 31, 2025, resulting in significant losses for investors [3]. Allegations in the Lawsuit - The class action complaint alleges that Tronox made materially false and misleading statements and failed to disclose adverse facts about its business and operations [4]. - Specific allegations include the company's inability to accurately forecast demand for its products and the promotion of unrealistic margin projections based on expected sales volume increases [4].

SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of LifeMD, Inc. (NASDAQ: LFMD) (“LifeMD” or the “Company”). The lawsuit seeks to recover losses on behalf of investors who purchased the Company’s securities between May 7, 2025, and August 5, 2025. If you purchased LifeMD securities and suffered losses, you have until October 27, 2025, to seek appointment as lead plaintiff. Investors who incurred significant losses a ...

https://zlk.com/pslra-1/c3-ai-inc-lawsuit-submission-form?prid=166636&wire=4 AI investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in C3.ai, Inc. ("C3.ai" or the "Company") (NYSE: AI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of C3.ai investors who were adversely affected by alleged securities fraud be ...

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2]. - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4].